DEC205+ dendritic cell-targeted tolerogenic vaccination promotes immune tolerance in experimental autoimmune arthritis

Journal of Immunology

Volumn 194, Issue 10, 2015, Pages 4804-4813

  Spiering, Rachel ^a   Margry, Bram ^a   Keijzer, Chantal ^a   Petzold, Cathleen ^b   Hoek, Aad ^a   Wagenaar Hilbers, Josée ^a   Van Der Zee, Ruurd ^a   Van Eden, Willem ^a   Kretschmer, Karsten ^b,c   Broere, Femke ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; PROTEOGLYCAN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ARTHRITIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GERMINAL CENTER; HELPER CELL; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; VACCINES;

EID: 84929103797     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400986     Document Type: Article

References (48)

1. Fox, D. A., A. Gizinski, R. Morgan, and S. K. Lundy. 2010. Cell-cell interactions in rheumatoid arthritis synovium. Rheum. Dis. Clin. North Am. 36: 311-323.
2. Lubberts, E. 2010. Th17 cytokines and arthritis. Semin. Immunopathol. 32: 43-53.
3. Dumont, F. J. 2004. Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 6: 318-330.
4. Goodstone, N. J., M. C. Doran, R. N. Hobbs, R. C. Butler, J. J. Dixey, and B. A. Ashton. 1996. Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Ann. Rheum. Dis. 55: 40-46.
5. Guerassimov, A., Y. Zhang, S. Banerjee, A. Cartman, J. Y. Leroux, L. C. Rosenberg, J. Esdaile, M. A. Fitzcharles, and A. R. Poole. 1998. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis Rheum. 41: 1019-1025.
6. Li, N. L., D. Q. Zhang, K. Y. Zhou, A. Cartman, J. Y. Leroux, A. R. Poole, and Y. P. Zhang. 2000. Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res. 10: 39-49.
7. Glant, T. T., K. Mikecz, A. Arzoumanian, and A. R. Poole. 1987. Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum. 30: 201-212.
8. Glant, T. T., and K. Mikecz. 2004. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol. Med. 102: 313-338.
9. Kaplan, C. D., Y. Cao, J. S. Verbeek, M. Tunyogi-Csapo, and A. Finnegan. 2005. Development of proteoglycan-induced arthritis is critically dependent on Fcγ receptor type III expression. Arthritis Rheum. 52: 1612-1619.
10. Kis-Toth, K., M. Radacs, K. Olasz, W. van Eden, K. Mikecz, and T. T. Glant. 2012. Arthritogenic T cells drive the recovery of autoantibody-producing B cell homeostasis and the adoptive transfer of arthritis in SCID mice. Int. Immunol. 24: 507-517.
11. + T cell reactivity. J. Immunol. 180: 4994-5003.
12. Bárdos, T., K. Mikecz, A. Finnegan, J. Zhang, and T. T. Glant. 2002. T and B cell recovery in arthritis adoptively transferred to SCID mice: antigen-specific activation is required for restoration of autopathogenic CD4+ Th1 cells in a syngeneic system. J. Immunol. 168: 6013-6021.
13. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
14. Hawiger, D., R. F. Masilamani, E. Bettelli, V. K. Kuchroo, and M. C. Nussenzweig. 2004. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695-705.
15. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219-1227.
16. 3+ regulatory T cells. J. Immunol. 181: 6923-6933.
17. + T cells into regulatory T cells and promotes immunotolerance in NOD mice. Rev. Diabet. Stud. 7: 47-61.
18. Stern, J. N., D. B. Keskin, Z. Kato, H. Waldner, S. Schallenberg, A. Anderson, H. von Boehmer, K. Kretschmer, and J. L. Strominger. 2010. Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc. Natl. Acad. Sci. USA 107: 17280-17285.
19. Bruder, D., A. M. Westendorf, W. Hansen, S. Prettin, A. D. Gruber, Y. Qian, H. von Boehmer, K. Mahnke, and J. Buer. 2005. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54: 3395-3401.
20. Kretschmer, K., T. S. Heng, and H. von Boehmer. 2006. De novo production of antigen-specific suppressor cells in vivo. Nat. Protoc. 1: 653-661.
21. Mahnke, K., Y. Qian, S. Fondel, J. Brueck, C. Becker, and A. H. Enk. 2005. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 65: 7007-7012.
22. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199: 815-824.
23. Boscardin, S. B., J. C. Hafalla, R. F. Masilamani, A. O. Kamphorst, H. A. Zebroski, U. Rai, A. Morrot, F. Zavala, R. M. Steinman, R. S. Nussenzweig, and M. C. Nussenzweig. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203: 599-606.
24. + dendritic cells for tolerogenic vaccination. Rev. Diabet. Stud. 9: 305-318.
25. Idoyaga, J., C. Fiorese, L. Zbytnuik, A. Lubkin, J. Miller, B. Malissen, D. Mucida, M. Merad, and R. M. Steinman. 2013. Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Invest. 123: 844-854.
26. Daniel, C., K. Wennhold, H. J. Kim, and H. von Boehmer. 2010. Enhancement of antigen-specific Treg vaccination in vivo. Proc. Natl. Acad. Sci. USA 107: 16246-16251.
27. Murad, Y. M., Z. Szabó, K. Ludányi, and T. T. Glant. 2005. Molecular manipulation with the arthritogenic epitopes of the G1 domain of human cartilage proteoglycan aggrecan. Clin. Exp. Immunol. 142: 303-311.
28. Buzás, E. I., A. Végvári, Y. M. Murad, A. Finnegan, K. Mikecz, and T. T. Glant. 2005. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis. Cell. Immunol. 235: 98-108.
29. Hanyecz, A., K. Olasz, O. Tarjanyi, P. Nemeth, K. Mikecz, T. T. Glant, and F. Boldizsar. 2014. Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis. Biomed Res Int 2014: 942148.
30. Berghmans, N., A. Nuyts, C. Uyttenhove, J. Van Snick, G. Opdenakker, and H. Heremans. 2011. Interferon-γ orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J. Interferon Cytokine Res. 31: 575-587.
31. Doodes, P. D., Y. Cao, K. M. Hamel, Y. Wang, R. L. Rodeghero, K. Mikecz, T. T. Glant, Y. Iwakura, and A. Finnegan. 2010. IFN-γ regulates the requirement for IL-17 in proteoglycan-induced arthritis. J. Immunol. 184: 1552-1559.
32. Doodes, P. D., Y. Cao, K. M. Hamel, Y. Wang, B. Farkas, Y. Iwakura, and A. Finnegan. 2008. Development of proteoglycan-induced arthritis is independent of IL-17. J. Immunol. 181: 329-337.
33. Marin, N., H. Eixarch, M. J. Mansilla, E. Rodríguez, M. Mecha, C. Guaza, J. C. Álvarez-Cermeño, X. Montalban, L. M. Villar, and C. Espejo. 2014. Antimyelin antibodies play an important role in the susceptibility to develop PLP-induced EAE. Clin. Exp. Immunol. 175: 202-207.
34. O'Neill, S. K., Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas, and A. Finnegan. 2007. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179: 5109-5116.
35. O'Neill, S. K., M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan. 2005. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174: 3781-3788.
36. Angyal, A., C. Egelston, T. Kobezda, K. Olasz, A. László, T. T. Glant, and K. Mikecz. 2010. Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. Arthritis Res. Ther. 12: R44.
37. Kaplan, C. D., S. K. O'Neill, T. Koreny, M. Czipri, and A. Finnegan. 2002. Development of inflammation in proteoglycan-induced arthritis is dependent on FcγR regulation of the cytokine/chemokine environment. J. Immunol. 169: 5851-5859.
38. Berlo, S. E., T. Guichelaar, C. B. Ten Brink, P. J. van Kooten, F. Hauet-Broeren, K. Ludanyi, W. van Eden, C. P. Broeren, and T. T. Glant. 2006. Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis Rheum. 54: 2423-2433.
39. Hanyecz, A., S. E. Berlo, S. Szántó, C. P. Broeren, K. Mikecz, and T. T. Glant. 2004. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthritis Rheum. 50: 1665-1676.
40. Schallenberg, S., C. Petzold, J. Riewaldt, and K. Kretschmer. 2013. Regulatory T cell-based immunotherapy: prospects of antigen-specific tolerance induction. In Medical Advancements in Aging and Regenerative Technologies: Clinical Tools and Applications. A. Daskalaki, ed. IGI Global, Hershey, PA, p. 112-136.
41. Kaplan, C., J. C. Valdez, R. Chandrasekaran, H. Eibel, K. Mikecz, T. T. Glant, and A. Finnegan. 2002. Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res. 4: 54-58.
42. Holló, K., T. T. Glant, M. Garzó, A. Finnegan, K. Mikecz, and E. Buzás. 2000. Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis. Clin. Exp. Immunol. 120: 167-173.
43. Kool, M., T. Soullié, M. van Nimwegen, M. A. M. Willart, F. Muskens, S. Jung, H. C. Hoogsteden, H. Hammad, and B. N. Lambrecht. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205: 869-882.
44. Tangye, S. G., C. S. Ma, R. Brink, and E. K. Deenick. 2013. The good, the bad and the ugly - TFH cells in human health and disease. Nat. Rev. Immunol. 13: 412-426.
45. Ramiscal, R. R., and C. G. Vinuesa. 2013. T-cell subsets in the germinal center. Immunol. Rev. 252: 146-155.
46. de Jong, H., S. E. Berlo, P. Hombrink, H. G. Otten, W. van Eden, F. P. Lafeber, A. H. Heurkens, J. W. Bijlsma, T. T. Glant, and B. J. Prakken. 2010. Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 69: 255-262.
47. Zou, J., Y. Zhang, A. Thiel, M. Rudwaleit, S. L. Shi, A. Radbruch, R. Poole, J. Braun, and J. Sieper. 2003. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 42: 846-855.
48. Zheng, X., C. Vladau, X. Zhang, M. Suzuki, T. E. Ichim, Z. X. Zhang, M. Li, E. Carrier, B. Garcia, A. M. Jevnikar, and W. P. Min. 2009. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 113: 2646-2654.